GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
No treatment |
Permissive
Robust
|
Homo sapiens |
GSE81714
...
|
MA1105.2
|
GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
control |
Permissive
Robust
|
Homo sapiens |
GSE109820
...
|
MA1105.2
|
GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
control |
Permissive
Robust
|
Homo sapiens |
GSE109820
...
|
MA1105.2
|
GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
control |
Permissive
Robust
|
Homo sapiens |
GSE109820
...
|
MA1105.2
|
GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
100nm E2 (45 min) |
Permissive
Robust
|
Homo sapiens |
GSE109820
...
|
MA1105.2
|
GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
100nm E2 (45 min) |
Permissive
Robust
|
Homo sapiens |
GSE109820
...
|
MA1105.2
|
GRHL2 |
MCF7 (Invasive ductal breast carcinoma) |
100nm E2 (45 min) |
Permissive
Robust
|
Homo sapiens |
GSE109820
...
|
MA1105.2
|
GRHL2 |
MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) |
Treatment: 45 min ethanol |
Permissive
Robust
|
Homo sapiens |
GSE113092
...
|
MA1105.2
|
GRHL2 |
MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) |
Treatment: 45 min ethanol |
Permissive
Robust
|
Homo sapiens |
GSE113092
...
|
MA1105.2
|
GRHL2 |
MCF7 TamR (invasive ductal breast carcinoma Tamoxifen resistant) |
Treatment: 45 min ethanol |
Permissive
Robust
|
Homo sapiens |
GSE113092
...
|
MA1105.2
|
GRHL2 |
MCF7 WS8 cells |
Treatment: 45 min ethanol |
Permissive
Robust
|
Homo sapiens |
GSE113092
...
|
MA1105.2
|
GRHL2 |
MCF7 WS8 cells |
Treatment: 45 min ethanol |
Permissive
Robust
|
Homo sapiens |
GSE113092
...
|
MA1105.2
|
GRHL2 |
MCF7 WS8 cells |
Treatment: 45 min ethanol |
Permissive
Robust
|
Homo sapiens |
GSE113092
...
|
MA1105.2
|
GRHL2 |
epiblast cells |
Origin: cell line V6.5 ESCs Treatment: grown in 2i, day 3 (GSKi and MEKi), doxycycline was added at 0.5ug/ml for 24hrs Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE92745
...
|
MA1105.2
|
GRHL2 |
epiblast cells |
Origin: cell line V6.5 ESCs Treatment: grown in 2i, day 3 (GSKi and MEKi), doxycycline was added at 0.5ug/ml for 24hrs Genotype: wildtype |
Permissive
Robust
|
Mus musculus |
GSE92745
...
|
MA1105.2
|
GRHL2 |
epiblast cells |
Origin: cell line V6.5 ESCs Treatment: grown in 2i, day 3 (GSKi and MEKi), doxycycline was added at 0.5ug/ml for 24hrs Genotype: GRHL2 knockout |
Permissive
Robust
|
Mus musculus |
GSE92745
...
|
MA1105.2
|
GRHL2 |
epiblast cells |
Origin: cell line V6.5 ESCs Treatment: grown in 2i, day 3 (GSKi and MEKi), doxycycline was added at 0.5ug/ml for 24hrs Genotype: GRHL2 knockout |
Permissive
Robust
|
Mus musculus |
GSE92745
...
|
MA1105.2
|
GRHL2 |
placenta |
|
Permissive
Robust
|
Mus musculus |
GSE65962
...
|
MA1105.2
|
GRHL2 |
|
|
Permissive
Robust
|
Homo sapiens |
GSE46194
|
MA1105.2
|
GRHL2 |
OVCA429 (ovarian cystadenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE71018
|
MA1105.2
|
GRHL2 |
OVCAR3 (high grade ovarian serous adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE71018
|
MA1105.2
|
GRHL2 |
PEO1 (ovarian cystadenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE71018
|
MA1105.2
|